ImmunoGen, Inc. (NASDAQ:IMGN) Q1 2023 Earnings Conference Call April 28, 2023 8:00 AM ET

Company Participants

Anabel Chan - Head, Investor Relations

Mark Enyedy - President & Chief Executive Officer

Anna Berkenblit - Chief Medical Officer

Renee Lentini - Interim-Chief Financial Officer

Michael Vasconcelles - Executive Vice President of Research, Development & Medical Affairs

Todd Talarico - Vice President of Market Access

Conference Call Participants

John Newman - Canaccord Genuity

Michael Schmidt - Guggenheim Partners

Etzer Darout - BMO

Andy Hsieh - William Blair

Boris Peaker - Cowen

Peter Lawson - Barclays

Kelly Shi - Jefferies

Asthika Goonewardene - Truist

Joe Catanzaro - Piper Sandler

Operator

Good morning and welcome to ImmunoGen's First Quarter 2023 Financial and Operating Results Conference Call. Today's conference is being recorded.

At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.

Anabel Chan

Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress, and first quarter financial results. This press release the recording of this call, and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com.

With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Renee Lentini, our Interim CFO; Michael Vasconcelles, our EVP of Research, Development and Medical Affairs; Isabel Kalofonos, our Chief Commercial Officer; and Todd Talarico, our VP of Market Access will also join us for Q&A.

During today's call, we will review recent accomplishments for the business, our financial results and highlight upcoming anticipated events. We will be making forward-looking statements based on our current expectations and beliefs. These statements are subject to risks and uncertainties and our actual results may differ materially.

Please consult the risk outlined in our press release issued this morning in the Risk Factors section of our most recent annual report on Form 10-K and in our other SEC filings, which are available at sec.gov and immunogen.com.

And with that, I'll turn the call over to Mark.

Mark Enyedy

Thanks, Anabel. Good morning, everyone, and thank you for joining us today. I'd like to preface this call by saying that the focus of today's discussion will be on ELAHERE's commercial performance and on our ongoing development programs beyond MIRASOL. We expect to share top line MIRASOL data within the next couple of weeks, so we'll refrain from commenting on this trial and respectfully ask that you hold any questions.